Drug Trial Radar · NCT06917690
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Apr 18, 2025
Primary completion
Mar 2026
Study completion Sep 2029
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are: * Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds? * Are there any medical problems when using Oleogel-S10 gel? * How much of the drug ends up in your blood? The study has 2 parts. In Part 1, participants will: * Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days. * Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.
Conditions
- Epidermolysis Bullosa
- Junctional Epidermolysis Bullosa
- Epidermolysis Bullosa, Dystrophic
- Epidermolysis Bullosa, Junctional
- Skin Abnormalities
- Connective Tissue Disease
- Collagen Diseases
- Skin Diseases
- Genetic Diseases, Inborn
- Congenital Abnormalities
Interventions
Oleogel-S10Drug
Topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of Oleogel-S10 in Part ITime frame: Enrollment to 45 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Fukuoka Children's Hospital - Dermatology
Fukuoka, Japan · Recruiting
Kurume University Hospital
Fukuoka, Japan · Recruiting
Kobe University Hospital
Kobe, Japan · Recruiting
Niigata University Medical and Dental Hospital
Niigata, Japan · Recruiting
Toho University Omori Medical Center
Ōta-ku, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.